{"id":470236,"date":"2021-04-01T17:33:29","date_gmt":"2021-04-01T21:33:29","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=470236"},"modified":"2021-04-01T17:33:29","modified_gmt":"2021-04-01T21:33:29","slug":"chembio-announces-u-s-commercial-launch-of-diagnostic-tool-to-differentiate-covid-19-and-flu","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/chembio-announces-u-s-commercial-launch-of-diagnostic-tool-to-differentiate-covid-19-and-flu\/","title":{"rendered":"Chembio Announces U.S. Commercial Launch of Diagnostic Tool to Differentiate COVID-19 and Flu"},"content":{"rendered":"<h2>\nIn-licensed Rapid Point-of-Care Test Available for Use in Detecting COVID-19 Antigens, Flu A and Flu B from a Single Patient Sample in 15 Minutes<br \/>\n<\/h2>\n<div class=\"mw_release\">\n<p align=\"justify\">HAUPPAUGE, N.Y., April  01, 2021  (GLOBE NEWSWIRE) &#8212; Chembio Diagnostics, Inc. (Nasdaq:\u00a0CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today announced the commercial launch of an FDA Emergency Use Authorization-approved, in-licensed rapid point-of-care COVID-19\/Flu A&amp;B test, for use in decentralized and traditional testing settings. Product inventory is on-hand and immediately available for shipment to customers across the United States.<\/p>\n<p>The rapid immunoassay test is approved for use in laboratories with a CLIA waiver license, produces results in 15 minutes and requires no instrumentation. The test simultaneously differentiates SARS-CoV-2 antigens and influenza Type A and Type B infections from a single swab.<\/p>\n<p align=\"left\">\u201cAs COVID-19 converges with the flu, it is critical for physicians to be able to quickly differentiate between these viruses at the point-of-care, which present with nearly identical symptoms, in order to take appropriate clinical actions and maximize efficient use of healthcare resources,\u201d said Charles Caso, Vice President of Sales and Marketing for Chembio. \u201cBased on recent research, we expect that the spread of COVID-19 will eventually transition from a pandemic to an endemic state, with the virus surviving among the population at a lower incidence. In this scenario, coupled with the return to normalcy in society, we see COVID-19 testing remaining a crucial and integral component of broader respiratory testing.\u201d<\/p>\n<p align=\"left\">\n        <strong>About Chembio Diagnostics<\/strong><br \/>\n        <br \/>Chembio is a leading point-of-care diagnostics company focused on detecting and diagnosing infectious diseases, including COVID-19, sexually transmitted disease, and fever and tropical disease. Coupled with Chembio\u2019s extensive scientific expertise, its novel DPP technology offers broad market applications beyond infectious disease. Chembio\u2019s products are sold globally, directly and through distributors, to hospitals and clinics, physician offices, clinical laboratories, public health organizations, government agencies, and consumers. Learn more at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=7Y9qFRYtE-n9PLRRuTUxsPFT5bkYshPJQckl0BuAYy9juo-2ftt4tvpkKJ0cddZ9hQo3fubzsCLv4Xdt7h51rA==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">www.chembio.com<\/a>.<\/p>\n<p>\n        <em>DPP is Chembio\u2019s registered trademark, and the Chembio logo is Chembio\u2019s trademark. For convenience, these trademarks appear in this release without \u00ae or \u2122 symbols, but that practice does not mean that Chembio will not assert, to the fullest extent under applicable law, its rights to the trademark.<\/em>\n      <\/p>\n<p>\n        <strong>Contact:\u00a0<\/strong>\u00a0<br \/>Brian Johnston<br \/>Gilmartin Group<br \/>631-807-1986<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=DHx3YfOpupPKtySg2JaiYwhM_mRvIkpkacTlx01do40XhHL6dkU_ZNYc3TQNzzyufZz-muUs0RNZA073HDK897YDBZ2FSAlgtPgbZObFA14=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">investor@chembio.com<\/a><\/p>\n<p>      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIxMDU3MCM0MTAzMjk0IzIwMDYxMDE=\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/77164ee5-e6bd-4ad9-9c14-c947a15d08e3\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>In-licensed Rapid Point-of-Care Test Available for Use in Detecting COVID-19 Antigens, Flu A and Flu B from a Single Patient Sample in 15 Minutes HAUPPAUGE, N.Y., April 01, 2021 (GLOBE NEWSWIRE) &#8212; Chembio Diagnostics, Inc. (Nasdaq:\u00a0CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today announced the commercial launch of an FDA Emergency Use Authorization-approved, in-licensed rapid point-of-care COVID-19\/Flu A&amp;B test, for use in decentralized and traditional testing settings. Product inventory is on-hand and immediately available for shipment to customers across the United States. The rapid immunoassay test is approved for use in laboratories with a CLIA waiver license, produces results in 15 minutes and requires no instrumentation. The test simultaneously differentiates SARS-CoV-2 antigens and influenza Type A and &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/chembio-announces-u-s-commercial-launch-of-diagnostic-tool-to-differentiate-covid-19-and-flu\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Chembio Announces U.S. Commercial Launch of Diagnostic Tool to Differentiate COVID-19 and Flu&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-470236","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Chembio Announces U.S. Commercial Launch of Diagnostic Tool to Differentiate COVID-19 and Flu - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/chembio-announces-u-s-commercial-launch-of-diagnostic-tool-to-differentiate-covid-19-and-flu\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Chembio Announces U.S. Commercial Launch of Diagnostic Tool to Differentiate COVID-19 and Flu - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"In-licensed Rapid Point-of-Care Test Available for Use in Detecting COVID-19 Antigens, Flu A and Flu B from a Single Patient Sample in 15 Minutes HAUPPAUGE, N.Y., April 01, 2021 (GLOBE NEWSWIRE) &#8212; Chembio Diagnostics, Inc. (Nasdaq:\u00a0CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today announced the commercial launch of an FDA Emergency Use Authorization-approved, in-licensed rapid point-of-care COVID-19\/Flu A&amp;B test, for use in decentralized and traditional testing settings. Product inventory is on-hand and immediately available for shipment to customers across the United States. The rapid immunoassay test is approved for use in laboratories with a CLIA waiver license, produces results in 15 minutes and requires no instrumentation. The test simultaneously differentiates SARS-CoV-2 antigens and influenza Type A and &hellip; Continue reading &quot;Chembio Announces U.S. Commercial Launch of Diagnostic Tool to Differentiate COVID-19 and Flu&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/chembio-announces-u-s-commercial-launch-of-diagnostic-tool-to-differentiate-covid-19-and-flu\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-04-01T21:33:29+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIxMDU3MCM0MTAzMjk0IzIwMDYxMDE=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/chembio-announces-u-s-commercial-launch-of-diagnostic-tool-to-differentiate-covid-19-and-flu\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/chembio-announces-u-s-commercial-launch-of-diagnostic-tool-to-differentiate-covid-19-and-flu\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Chembio Announces U.S. Commercial Launch of Diagnostic Tool to Differentiate COVID-19 and Flu\",\"datePublished\":\"2021-04-01T21:33:29+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/chembio-announces-u-s-commercial-launch-of-diagnostic-tool-to-differentiate-covid-19-and-flu\\\/\"},\"wordCount\":386,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/chembio-announces-u-s-commercial-launch-of-diagnostic-tool-to-differentiate-covid-19-and-flu\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIxMDU3MCM0MTAzMjk0IzIwMDYxMDE=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/chembio-announces-u-s-commercial-launch-of-diagnostic-tool-to-differentiate-covid-19-and-flu\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/chembio-announces-u-s-commercial-launch-of-diagnostic-tool-to-differentiate-covid-19-and-flu\\\/\",\"name\":\"Chembio Announces U.S. Commercial Launch of Diagnostic Tool to Differentiate COVID-19 and Flu - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/chembio-announces-u-s-commercial-launch-of-diagnostic-tool-to-differentiate-covid-19-and-flu\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/chembio-announces-u-s-commercial-launch-of-diagnostic-tool-to-differentiate-covid-19-and-flu\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIxMDU3MCM0MTAzMjk0IzIwMDYxMDE=\",\"datePublished\":\"2021-04-01T21:33:29+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/chembio-announces-u-s-commercial-launch-of-diagnostic-tool-to-differentiate-covid-19-and-flu\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/chembio-announces-u-s-commercial-launch-of-diagnostic-tool-to-differentiate-covid-19-and-flu\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/chembio-announces-u-s-commercial-launch-of-diagnostic-tool-to-differentiate-covid-19-and-flu\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIxMDU3MCM0MTAzMjk0IzIwMDYxMDE=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIxMDU3MCM0MTAzMjk0IzIwMDYxMDE=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/chembio-announces-u-s-commercial-launch-of-diagnostic-tool-to-differentiate-covid-19-and-flu\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Chembio Announces U.S. Commercial Launch of Diagnostic Tool to Differentiate COVID-19 and Flu\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Chembio Announces U.S. Commercial Launch of Diagnostic Tool to Differentiate COVID-19 and Flu - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/chembio-announces-u-s-commercial-launch-of-diagnostic-tool-to-differentiate-covid-19-and-flu\/","og_locale":"en_US","og_type":"article","og_title":"Chembio Announces U.S. Commercial Launch of Diagnostic Tool to Differentiate COVID-19 and Flu - Market Newsdesk","og_description":"In-licensed Rapid Point-of-Care Test Available for Use in Detecting COVID-19 Antigens, Flu A and Flu B from a Single Patient Sample in 15 Minutes HAUPPAUGE, N.Y., April 01, 2021 (GLOBE NEWSWIRE) &#8212; Chembio Diagnostics, Inc. (Nasdaq:\u00a0CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today announced the commercial launch of an FDA Emergency Use Authorization-approved, in-licensed rapid point-of-care COVID-19\/Flu A&amp;B test, for use in decentralized and traditional testing settings. Product inventory is on-hand and immediately available for shipment to customers across the United States. The rapid immunoassay test is approved for use in laboratories with a CLIA waiver license, produces results in 15 minutes and requires no instrumentation. The test simultaneously differentiates SARS-CoV-2 antigens and influenza Type A and &hellip; Continue reading \"Chembio Announces U.S. Commercial Launch of Diagnostic Tool to Differentiate COVID-19 and Flu\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/chembio-announces-u-s-commercial-launch-of-diagnostic-tool-to-differentiate-covid-19-and-flu\/","og_site_name":"Market Newsdesk","article_published_time":"2021-04-01T21:33:29+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIxMDU3MCM0MTAzMjk0IzIwMDYxMDE=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/chembio-announces-u-s-commercial-launch-of-diagnostic-tool-to-differentiate-covid-19-and-flu\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/chembio-announces-u-s-commercial-launch-of-diagnostic-tool-to-differentiate-covid-19-and-flu\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Chembio Announces U.S. Commercial Launch of Diagnostic Tool to Differentiate COVID-19 and Flu","datePublished":"2021-04-01T21:33:29+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/chembio-announces-u-s-commercial-launch-of-diagnostic-tool-to-differentiate-covid-19-and-flu\/"},"wordCount":386,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/chembio-announces-u-s-commercial-launch-of-diagnostic-tool-to-differentiate-covid-19-and-flu\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIxMDU3MCM0MTAzMjk0IzIwMDYxMDE=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/chembio-announces-u-s-commercial-launch-of-diagnostic-tool-to-differentiate-covid-19-and-flu\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/chembio-announces-u-s-commercial-launch-of-diagnostic-tool-to-differentiate-covid-19-and-flu\/","name":"Chembio Announces U.S. Commercial Launch of Diagnostic Tool to Differentiate COVID-19 and Flu - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/chembio-announces-u-s-commercial-launch-of-diagnostic-tool-to-differentiate-covid-19-and-flu\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/chembio-announces-u-s-commercial-launch-of-diagnostic-tool-to-differentiate-covid-19-and-flu\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIxMDU3MCM0MTAzMjk0IzIwMDYxMDE=","datePublished":"2021-04-01T21:33:29+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/chembio-announces-u-s-commercial-launch-of-diagnostic-tool-to-differentiate-covid-19-and-flu\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/chembio-announces-u-s-commercial-launch-of-diagnostic-tool-to-differentiate-covid-19-and-flu\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/chembio-announces-u-s-commercial-launch-of-diagnostic-tool-to-differentiate-covid-19-and-flu\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIxMDU3MCM0MTAzMjk0IzIwMDYxMDE=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIxMDU3MCM0MTAzMjk0IzIwMDYxMDE="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/chembio-announces-u-s-commercial-launch-of-diagnostic-tool-to-differentiate-covid-19-and-flu\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Chembio Announces U.S. Commercial Launch of Diagnostic Tool to Differentiate COVID-19 and Flu"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/470236","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=470236"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/470236\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=470236"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=470236"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=470236"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}